TD Cowen Names its Top Pick in the Biotechnology Sector

TD Cowen named Rhythm Pharmaceuticals its top biotech pick and set a $130 price target after the company reported strong Phase 2 results for Imcivree in Prader-Willi syndrome. The six-month data showed clinically meaningful improvement across key endpoints, including a 3% mean BMI reduction and meaningful hyperphagia improvement in 9 of 11 patients, supporting Phase 3 development. The news is constructive for RYTM and may support the stock, though it is still a single-name analyst call rather than a broader sector event.

Analysis

This reads less like a generic biotech upgrade and more like a de-risking event for a single-asset story: the market is being told the program is now mature enough that phase-3 probability is materially higher, which should compress the discount rate on the lead asset and pull forward peak-sales expectations. The second-order effect is that valuation may shift from “platform optionality” to “commercial execution,” which usually expands the investor base from event-driven biotech funds to quality-growth holders willing to underwrite longer-duration cash flows.

The sharpest relative beneficiaries are likely adjacent obesity/rare-disease names with clean catalysts, because capital will rotate toward high-conviction clinical data while weaker programs get punished for lacking similar signal quality. Suppliers and trial-service vendors with exposure to late-stage enrollment in rare disease could also see incremental demand if this data accelerates follow-on studies, but the bigger read-through is competitive: any company targeting hyperphagia or severe obesity endpoints now has a higher proof bar for differentiation.

The main risk is not the next readout but the translation from small, open-label/early-stage signal to broader phase-3 reproducibility and payer acceptance. Over the next 3-9 months, the stock can continue to rerate if management converts this into an efficient phase-3 design and clean regulatory path; over 12-24 months, the key failure mode is that efficacy remains strong but label economics disappoint due to patient selection, pricing, or adherence issues. Consensus may be underestimating how much of the upside is already in the science and how much still depends on commercial math.

Near term, the setup favors momentum, but it is vulnerable to a classic biotech air-pocket if the move becomes too crowded ahead of formal next-step guidance. The best-risk trade is to own the name into the next regulatory/clinical milestone rather than chase post-gap strength, while pairing it against a basket of lower-quality biotech names that lack comparable late-stage visibility.

Key Decisions for Investors

• Maintain/establish a tactical long in RYTM for the next 1-3 months, but size it as a catalyst trade rather than a core hold; upside remains meaningful if phase-3 timing and design are confirmed, while downside is capped unless the development path changes materially.
• Use call spreads in RYTM instead of outright stock if entering after the gap: target 3-6 month tenor to capture further rerating while limiting drawdown if the move stalls on valuation.
• Pair trade: long RYTM / short a basket of lower-conviction biotech names with nearer-term financing risk or weaker clinical visibility over the next 1-2 quarters; the spread should widen if capital rotates into quality data.
• Trim into strength if RYTM rallies another 15-20% before the next substantive update; that is where the market typically prices in too much of the phase-3 success case before the hard work of execution begins.
• Set a downside trigger on any delay in phase-3 guidance or trial design clarity over the next 4-8 weeks; that would be the first signal that the market has moved ahead of the facts.